Antenatal management of HNF4A-MODY and INSR mutations in pregnancy
Abstract
We report the case of a pregnant woman with coexisting pathogenic hepatocyte nuclear factor 4 alpha (HNF4A) and insulin receptor (INSR) gene variants. A 25-year-old lean Caucasian gravida 1, para 0 (G1P0) woman with a history of early-onset diabetes and features of insulin resistance, was referred at 6 weeks' gestation. Molecular testing confirmed pathogenic variants in HNF4A and INSR. Noninvasive prenatal testing predicted fetal inheritance of the HNF4A variant. Despite good maternal glycemic control and relatively low insulin requirements, the infant was macrosomic and developed persistent postnatal hypoglycemia requiring prolonged diazoxide therapy. This case highlights the importance of early recognition of monogenic diabetes in pregnancy, the potential utility of noninvasive prenatal testing, and the observation of persistent hyperinsulinemia beyond the neonatal period in HNF4A-related diabetes.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.